Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Our 2025 study in JMIR Formative Research examined 12-month outcomes for participants using semaglutide with behavioural support and found 1 : 19.1% average weight loss at 12 months for active subscribers 77.7% achieved at least 10% weight loss 61.5% achieved at least 15% weight loss 69% reported no side effects by month 12 These are completer results (people who stayed on the programme for 12 months), not intent-to-treat
Meanwhile, while Ozempic seems like an overnight success story to most of us, its actually been around for more than a decade
Weeks 13 through 16: 10 mg once weekly
Final Thoughts Retatrutide could be a major development in the world of weight loss treatments, offering a triple-action approach that may outperform existing medicines
Wegovy injection has the longest track record, including FDA approval for cardiovascular risk reduction in some patients
Data on new-generation amylin analogs Among the companies developing amylin analogs, Novo Nordisk, the pioneer of GLP-1s, is furthest along
US$ 20.54
US$ 22.73
US$ 23.28
US$ 21.71
US$ 26.92
US$ 23.86
